METHYLATION OF SRD5A2 PROMOTER PREDICTS A BETTER OUTCOME FOR PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Deng, Tuo
Lin, Xueming
Wu, Shulin
Zhang, Zhenwei
Wu, Chin-Lee
Yan, Liying
Taplin, Mary-Ellen
Wang, Zongwei
Olumi, Aria
机构：
来源：
JOURNAL OF UROLOGY | 2019年 / 201卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP81-16
引用
收藏
页码：E1178 / E1179
页数：2
相关论文
共 50 条
  • [1] Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy
    Wang, Zongwei
    Deng, Tuo
    Long, Xingbo
    Lin, Xueming
    Wu, Shulin
    Wang, Hongbo
    Ge, Rongbin
    Zhang, Zhenwei
    Wu, Chin-Lee
    Taplin, Mary-Ellen
    Olumi, Aria F.
    PLOS ONE, 2020, 15 (03):
  • [2] METHYLATION OF SRD5A2 PROMOTER PREDICTS A BETTER OUTCOME FOR PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
    Wang, Zongwei
    Deng, Tuo
    Lin, Xueming
    Wu, Shulin
    Zhang, Zhenwei
    Wu, Chin-Lee
    Taplin, Mary-Ellen
    Olumi, Aria
    JOURNAL OF UROLOGY, 2020, 203 : E560 - E560
  • [3] The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism
    Shiota, M.
    Fujimoto, N.
    Yokomizo, A.
    Takeuchi, A.
    Kashiwagi, E.
    Dejima, T.
    Kiyoshima, K.
    Inokuchi, J.
    Tatsugami, K.
    Eto, M.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (02) : 191 - 196
  • [4] The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism
    M Shiota
    N Fujimoto
    A Yokomizo
    A Takeuchi
    E Kashiwagi
    T Dejima
    K Kiyoshima
    J Inokuchi
    K Tatsugami
    M Eto
    Prostate Cancer and Prostatic Diseases, 2016, 19 : 191 - 196
  • [5] MISSENSE POLYMORPHISM IN SRD5A2 IN COMBINATION WITH HSD3B1 VARIATION IS ASSOCIATED WITH OUTCOME OF CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE
    Shiota, Masaki
    Akamatsu, Shunsuke
    Narita, Shintaro
    Sumiyoshi, Takayuki
    Fujiwara, Maki
    Uchiumi, Takeshi
    Ogawa, Osamu
    Habuchi, Tomonori
    Eto, Masatoshi
    JOURNAL OF UROLOGY, 2020, 203 : E122 - E122
  • [6] Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
    Hussain, Arif
    Tripathi, Abhishek
    Pieczonka, Christopher
    Cope, Diane
    McNatty, Andrea
    Logothetis, Christopher
    Guise, Theresa
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (02) : 290 - 300
  • [7] Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
    Arif Hussain
    Abhishek Tripathi
    Christopher Pieczonka
    Diane Cope
    Andrea McNatty
    Christopher Logothetis
    Theresa Guise
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 290 - 300
  • [8] Evaluation of maintenance of the common androgen deprivation therapy with the new antiandrogen therapy in patients with castration-resistant prostate cancer: a systematic review
    Carla Manzoni Salgado
    Herney Andrés Garcia-Perdomo
    Leonardo O. Reis
    International Urology and Nephrology, 2022, 54 : 1187 - 1192
  • [9] Evaluation of maintenance of the common androgen deprivation therapy with the new antiandrogen therapy in patients with castration-resistant prostate cancer: a systematic review
    Salgado, Carla Manzoni
    Garcia-Perdomo, Herney Andres
    Reis, Leonardo O.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (06) : 1187 - 1192
  • [10] Hypercholesterolemia Is Associated with a Shorter Time to Castration-Resistant Prostate Cancer in Patients Who Have Undergone Androgen Deprivation Therapy
    Jeon, Jong Chul
    Park, Jaeyoung
    Park, Sungchan
    Moon, Kyung Hyun
    Cheon, Sang Hyeon
    Park, Sejun
    WORLD JOURNAL OF MENS HEALTH, 2016, 34 (01): : 28 - 33
12345